Contraceptive Market

Contraceptive Market Size, Market Forecast and Outlook By FMI

The contraceptive market was valued at USD 20.90 billion in 2025, projected to reach USD 22.07 billion in 2026, and is forecast to expand to USD 38.06 billion by 2036 at a 5.6% CAGR. Government-funded contraception programs in both developed and emerging economies have maintained a stable demand floor for institutional channel sales.

Summary of Contraceptive Market

• Market Snapshot
  • The contraceptive market is valued at USD Billion 20.90 billion in 2025 and is projected to reach USD Billion 38.06 billion by 2036.
  • The industry is expected to grow at a 5.6% CAGR from 2026 to 2036, creating an incremental opportunity of USD Billion 15.99 billion.
  • The market is a regulation-intensive, demographically segmented category where government family planning policies, insurance coverage mandates, and evolving consumer preferences across gender-specific product categories define competitive dynamics.
• Demand and Growth Drivers
  • Demand is expanding as government family planning programs in emerging economies increase contraceptive access through subsidized distribution and insurance coverage mandates.
  • Adoption of long-acting reversible contraceptives is accelerating as healthcare systems recognize their cost-effectiveness and higher continuation rates compared to short-acting methods.
  • Growth is supported by increasing retail pharmacy and e-commerce distribution penetration, enabling self-directed contraceptive purchasing without clinic visits.
  • Among key countries, China at 6.1%, USA at 5.8%, India at 5.8%, Germany at 5.5%, Australia at 5.1%.
• Product and Segment View
  • The Contraceptive Market covers pharmaceutical and device-based products designed to prevent unintended pregnancy. Product categories include oral contraceptive pills, injectable contraceptives, topical contraceptives, condoms, diaphragms, contraceptive sponges, vaginal rings, cervical caps, subdermal implants, and intra-uterine devices.
  • Market scope includes prescription and over-the-counter contraceptive drugs and devices, covering both branded and generic formulations.
  • The scope excludes fertility treatments, assisted reproductive technologies, emergency contraception sold as standalone categories, and surgical sterilization procedures.
• Geography and Competitive Outlook
  • China and USA are the fastest-growing markets, while Germany and Australia represent mature demand bases with steady consumption patterns.
  • Competition is shaped by a fragmented vendor landscape, with key players including Reckitt Benckiser Group plc., Bayer AG, Pfizer Inc., Janssen Global Services, LLC, Teva Pharmaceutical Industries Ltd., Merck & Co., Inc., Mylan N.V..
  • Reckitt Benckiser Group plc. holds approximately 18% market share, positioning it as the category leader.
• Analyst Opinion at FMI
  • Sabyasachi Ghosh, Principal Consultant for Healthcare observe that: 'In my analysis, I have observed that the defining commercial tension in the contraceptive category is the widening gap between LARC adoption rates in markets with full insurance coverage versus those where out-of-pocket costs remain prohibitive. Pharmaceutical companies unable to secure formulary inclusion for next-generation implant and IUD products face progressive market share erosion as payer systems standardize on cost-effectiveness metrics. Distribution networks that fail to build direct-to-consumer digital channels will lose ground as contraceptive purchasing migrates from clinic-based dispensing to retail and e-commerce fulfillment.'
• Strategic Implications / Executive Takeaways
  • Pharmaceutical companies must accelerate regulatory submissions for extended-duration LARC products to capture formulary positions before payer standardization windows close.
  • Distribution network operators should expand digital fulfillment capabilities to capture the growing share of contraceptive purchases migrating to online and direct-to-consumer channels.
  • Public health procurement directors must evaluate total cost-of-ownership models comparing LARC devices against recurring oral contraceptive expenditure to optimize family planning program budgets.

Contraceptive Market Key Takeaways

Metric	Details
Industry Size (2026)	USD 22.07 billion
Industry Value (2036)	USD 38.06 billion
CAGR (2026-2036)	5.6%

Source: Future Market Insights, 2026

FMI analysts observe a pronounced shift toward long-acting reversible contraceptives (LARCs) including subdermal implants and IUDs, driven by their superior efficacy rates and lower long-term costs compared to daily-use products. Concurrently, male contraceptive research pipelines are expanding, though the immediate commercial impact remains concentrated in the condom category. Retail pharmacy and online sales channels are gaining share as consumer purchasing behavior shifts toward self-directed contraceptive access.

All major markets reflect differentiated growth trajectories. China at 6.1% CAGR, USA at 5.8% CAGR, India at 5.8% CAGR, Germany at 5.5% CAGR, Australia at 5.1% CAGR. Each country path is shaped by local regulatory frameworks, infrastructure maturity, and industry-specific demand patterns.

Contraceptive Market Definition

The Contraceptive Market covers pharmaceutical and device-based products designed to prevent unintended pregnancy. Product categories include oral contraceptive pills, injectable contraceptives, topical contraceptives, condoms, diaphragms, contraceptive sponges, vaginal rings, cervical caps, subdermal implants, and intra-uterine devices. These products serve both female and male populations through institutional and retail sales channels.

Contraceptive Market Inclusions

Market scope includes prescription and over-the-counter contraceptive drugs and devices, covering both branded and generic formulations. Global and regional market sizes for the forecast period 2026 to 2036 are covered, segmented by product type, gender, and sales channel.

Contraceptive Market Exclusions

The scope excludes fertility treatments, assisted reproductive technologies, emergency contraception sold as standalone categories, and surgical sterilization procedures. Contraceptive counseling services and digital fertility tracking applications are also excluded.

Contraceptive Market Research Methodology

• Primary Research: Analysts engaged with reproductive health procurement directors, pharmaceutical distribution managers, and family planning program coordinators across public and private healthcare systems.
• Desk Research: Data collection included WHO reproductive health surveillance reports, national family planning program publications, pharmaceutical regulatory approval databases, and insurance coverage mandate documentation.
• Market-Sizing and Forecasting: Baseline values derive from a bottom-up aggregation of contraceptive prescription volumes and OTC sales data, applying demographic adoption curves and policy-driven coverage expansion rates to project demand through 2036.
• Data Validation and Update Cycle: Projections are cross-validated against publicly reported pharmaceutical revenue data from leading contraceptive manufacturers and government family planning expenditure reports.

Key Trends Influencing the Contraceptive Market

Widespread Demand for Wearable Pregnancy Devices

• Due to increasing awareness and changes in women's lifestyles, wearable pregnancy gadgets that use passive technology to track baby movements are becoming increasingly common.
• From home ultrasounds to infant health monitors, wearable pregnancy gadgets serve various purposes from the first day of pregnancy to childbirth, providing parents with important information.
• Due to their cost, portability, and compact size, wearable pregnancy technology is becoming increasingly popular among hospitals and home healthcare providers. It tracks the progress of the fetus.
• The WHO estimates that Every day in 2023, over 700 women died from preventable causes related to pregnancy and childbirth., which is driving the market for wearable technology. Pregnancy complications are on the rise and affect both mother and child.
• Due to new care models, remote care, and the Internet of Things, wearable pregnancy gadgets are becoming prevalent, improving healthcare systems and extending maternity periods.

Adoption of Hormonal Contraception Simplifies the Pregnancy Scare

• Hormonal contraception is evolving and becoming prevalent due to the increased population and advancements in birth control technology. Hormonal pills containing estrogen and progesterone prevent pregnancy by blocking egg release, thinning the uterine lining, and thickening cervical mucus.
• Public awareness of sexual and reproductive health has led to an increased demand for hormonal contraception. Combination treatments, such as progestin and estrogen, suppress ovulation while thickening cervical mucus. These methods alter the uterine environment, making fertilization more difficult.
• Increased awareness, lifestyle changes, and government support have boosted the demand for hormonal contraception. Research and development programs aim to improve drugs and reduce side effects, with only two types currently available.
• Hormonal contraception remains a popular method for preventing pregnancy due to increased awareness, lifestyle changes, and government support programs.

Rise in Government Initiatives for Promoting Access to Family Planning

• Government initiatives promoting family planning and contraception are driving growth in the family planning market. Improved access enables individuals to make informed decisions about child spacing, leading to poverty reduction, gender equality, improved public health, and sustainable development.
• Non-profit organizations are providing funding, awareness programs, and contraception delivery in remote rural areas, escalating the reach and choices of family planning services. With support from international donors, NGOs can enhance outreach and distribution, particularly during health emergencies like global pandemics or crises of war.

Category-wise Insights

The following part offers an in-depth analysis of segments of the contraceptive market. The demand for drugs is significant, whereas the need for female contraceptive is anticipated to increase in 2024.

Contraceptive Drugs Cure up 41.50% of Market Share

Attributes	Details
Top Product Type	Drug
Market share in 2026	41.50%

The demand for contraceptive drugs is experiencing a 41.50% market share growth in 2026 due to augmented family planning and contraception efforts.

• Governments across the globe are prioritizing women's and children's health, leading to increased usage of contraceptive drugs and a significant rise in demand for these drugs, especially in emerging economies.
• The government's active involvement in promoting family planning and contraception has significantly boosted growth, empowering women and improving community health by increasing awareness and accessibility of these drugs.
• The demand for contraceptive drugs is predicted to continue rising in the coming decade as more governments and organizations invest in promoting safe and effective family planning methods.

Female Patients Develops 74.70% of Consumer Base

Attributes	Details
Top Gender	Female
Market share in 2026	74.70%

The demand for contraceptives for female patients is augmented, with a market share of 74.70% in 2026. Because female contraception techniques are more effective at preventing conception than male contraception, they are more widely used.

• The market is addressing STDs and unintended pregnancies to align with sustainable development goals, reducing maternal fatalities and promoting reproductive health. Evra and sub-dermal contraception implants cater to reproductive-age women, raising user awareness.
• Healthcare for female vitiligo patients is paramount as it impacts quality of life. Osteoporosis poses health risks, especially for postmenopausal women. Early detection and treatment are essential.
• Patient enrollment milestones indicate research progress in contraception options, including topical, diaphragm, and caps. Medications and surgery are vital for treating various health conditions.

Country-wise Insights

Based on the statistical data, industries in China and Germany are developing relatively in the upcoming decade. Simultaneously, the contraception industry in the United States and India is hitting the roof. The contraceptive sector in the ANZ region is anticipated to climb gradually in the upcoming decade.

Countries	CAGR from 2026 to 2036
United States	5.80%
Germany	5.50%
China	6.10%
India	5.80%
Australia and New Zealand	5.10%

The United States Offers a Fertile Ground for Contraception Solutions

The United States is anticipated to hold a CAGR of 5.8% from 2026 to 2036 in the contraceptive market.

In the United States, abstinence-only sex education is the primary form of sexual education, promoting abstinence from sex outside marriage or premarital sex in 39 states and the District of Columbia. However, this often excludes essential birth control measures and safe sex practices, contributing to an increase in teenage pregnancy rates due to the lack of comprehensive sex education.

Lack of accurate sex education in schools can hinder the adoption of products like female condoms, hindering market growth in the United States. Youth may remain unaware of these products, leading to their inability to use them. Therefore, it is essential to prioritize comprehensive sexual education in schools to empower young individuals to make decisions about their sexual health.

Germany Witnesses Evolving Demand for Contraceptive Devices

Demand for contraception devices in Germany is estimated to develop at a CAGR of 5.5%, with firms developing innovative solutions for birth control.

Germany's public health insurance is highly profitable, covering various health services, including birth control for women under 22. This provision ensures affordable and reliable contraception, allowing young women to make decisions about their reproductive health.

Germany's high prevalence of contraception use is attributed to its exceptional access to online information and average availability of contraception supplies, with most women using some form of birth control.

Germany achieved a 75.1 score in the 2020 European Contraception Policy Atlas, highlighting its commitment to providing comprehensive and accessible reproductive health services to its citizens.

Demand for Family Planning Awareness Skyrockets in China

China is on the brink of a significant market expansion in contraceptive devices and drugs, with a projected CAGR of 6.1% from 2026 to 2036.

Oral contraception, also known as birth control tablets or "the pill," is a popular form of contraception in China. These synthetic hormones, typically estrogen and progestin, limit ovulation and egg release, improving women's reproductive health and providing a safe and practical method of pregnancy avoidance.

China's oral contraceptives are highly effective, with less than one in 100 women experiencing unintentional pregnancy within a year of regular use, demonstrating their widespread use in the country.

China's oral contraception demand is increasing due to increased awareness, women's employment, STIs, LARC use, and Internet pharmacies.

Australia and New Zealand Cultivates Demand amidst STI Prevention Awareness

The pandemic has impacted women's access to contraception and abortion services in the ANZ region, leading to increased unintended pregnancies and a rise in contraception demand. The demand for contraception solutions in Australia and New Zealand is anticipated to register a CAGR of 5.1% through 2036.

The contraceptive market growth is primarily compelled by increasing sexually transmitted disease cases and Australia's government's and organizations' initiatives on contraception device use.

The prevalence of sexually transmitted diseases, including HIV, Gonorrhoea, Hepatitis, HPV, and PID, is predicted to boost demand for contraception devices, particularly in Australia and New Zealand.

Family Planning Applications Hits the Roof in India, Shaping Market Growth

The demand for contraception methods in India is foreseen to experience a CAGR of 5.8% from 2026 to 2036.

India's population growth boosts family planning and contraception demand, highlighting the importance of sexual and reproductive health, particularly among women, leading to increased demand for these services.

The Indian government has implemented various programs, including the National Family Planning Programme, to promote family planning and increase access to contraception methods.

Private companies are investing in contraception research and development. For instance, Reckitt Benckiser Group sold its contraception division to Mankind Pharma for USD 13 million in March 2023, providing access to various contraception, including the Durex brand.

Market Players Shaping the Outlook of the Contraceptive Market

The market is a competitive and rapidly evolving industry. Key players focus on diverse techniques to stay ahead of the competition and augment their presence in the market. Effective strategies are to acquire or collaborate with companies to improve their product portfolio and market penetration.

Companies, in addition to acquisitions and collaborations, prioritize gaining FDA approvals to ensure the safety and effectiveness of their products, giving them a competitive edge over competitors who may not have received the necessary approvals.

The leading companies are well known for their innovative products and commitment to providing safe and effective contraception to women globally. By leveraging these key strategies, they are able to stay ahead of the competition and continue to grow their businesses in a rapidly evolving market.

Key Companies

• Bayer AG Pfizer Inc.
• Janssen Global Services, LLC
• Teva Pharmaceutical Industries Ltd.
• Merck & Co., Inc.
• Mylan N.V.
• Allergan Plc.
• Reckitt Benckiser Group plc.
• Veru Inc.
• Church & Dwight Co., Inc.
• Medisafe Distribution Inc.
• Cooper Surgical, Inc.
• Mayer Laboratories, Inc.
• Pfizer Inc.
• The Female Health Company
• Exeltis USA, Inc.

Scope of the Report

Metric	Value
Quantitative Units	USD Billion 22.07 to USD Billion 38.06 billion, at a CAGR of 5.6%
Market Definition	The Contraceptive Market covers pharmaceutical and device-based products designed to prevent unintended pregnancy. Product categories include oral contraceptive pills, injectable contraceptives, topical contraceptives, condoms, diaphragms, contraceptive sponges, vaginal rings, cervical caps, subdermal implants, and intra-uterine devices.
Segmentation	Product: Drugs, Oral Contraceptive Pills, Injectable Contraceptive, Topical Contraceptive, Device, Condoms, Diaphragms, Contraceptive Sponges, Vaginal Rings, Cervical Cap, Subdermal Implants, Intra-uterine Devices; Gender: Female, Male; Sales Channel: Institutional Sales, Hospitals, Specialty Clinics, Retail Sales, Retail Pharmacy, Drug Stores, Supermarkets or Hypermarkets, Online Sales
Regions Covered	North America, Latin America, Europe, East Asia, South Asia, Oceania, Middle East & Africa
Countries Covered	USA, Germany, China, India, Australia, and 40 plus countries
Key Companies Profiled	Reckitt Benckiser Group plc., Bayer AG, Pfizer Inc., Janssen Global Services, LLC, Teva Pharmaceutical Industries Ltd., Merck & Co., Inc., Mylan N.V., Allergan Plc.
Forecast Period	2026 to 2036
Approach	Baseline values derive from a bottom-up aggregation of contraceptive prescription volumes and OTC sales data, applying demographic adoption curves and policy-driven coverage expansion rates to project demand through 2036.

Key Segments

By Product:

• Drugs
  • Oral Contraceptive Pills
  • Injectable Contraceptive
  • Topical Contraceptive
• Devices
  • Condoms
  • Diaphragms
  • Contraceptive Sponges
  • Vaginal Rings
  • Cervical Cap
  • Subdermal Implants
  • Intra-uterine Devices
    • Copper
    • Hormonal

By Gender:

• Female
• Male

By End User:

• Institutional Sales
  • Hospitals
  • Specialty Clinics
• Retail Sales
  • Retail Pharmacy
  • Drug Stores
  • Supermarkets or Hypermarkets
• Online Sales

By Region:

• North America
• Latin America
• Europe
• East Asia
• South Asia
• Oceania
• Middle East and Africa

Bibliography

• 1. World Health Organization. (2024). Family planning and contraception: Fact sheet update. WHO.
• 2. United Nations Population Fund. (2024). State of world population report. UNFPA.
• 3. USA Food and Drug Administration. (2024). Contraceptive device regulatory approval summaries. FDA.
• 4. European Medicines Agency. (2024). Hormonal contraceptive safety review update. EMA.
• 5. Reckitt Benckiser Group plc. (2025). 2024 annual report. Reckitt Benckiser.

This bibliography is provided for reader reference. The full Future Market Insights report contains the complete reference list with primary research documentation.